Event Participants
Executives
5 Arvind Bothra, Ganesh N. Nayak, Alok Garg, Sharvil P. Patel, Tushar Shroff
Analysts
8 Bino Pathiparampil, Damayanti Kerai, Kunal Dhamesha, Neha Manpuria, Saion Mukherjee, Surya Patra, Vishal Manchanda, 1 Unidentified participant
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹8,020 crores | +22% YoY; strong double-digit growth across all key businesses, building on a formidable FY26 base |
| EBITDA | ₹1,930 crores | Margin of 24.1%, in line with guidance; margin held despite acquisition-related opex and Mirabegron royalty |
| Net Profit | ₹940 crores | Profitability sustained alongside higher depreciation (acquisition amortization) and investment spend |
| Net Debt/EBITDA | 0.7x | Slight up from prior year; reflects borrowing for Assertio acquisition and wellness land purchase |
| India Branded Formulations | ~₹2,900 cr Q1 (imputed) | +20% YoY; outgrew IPM for 3 consecutive years; cardiology, diabetology, gynecology, anti-infectives, pain, oncology, nephrology all grew faster than market; chronic+sub-chronic mix at 54.2% MAT June 2026 |
| International Market Formulations | ₹970 crores | +34% YoY; driven by emerging markets strength, EU (France, Spain, faster-than-expected UK scale-up), and new geography entries |
| North America (US + Canada) | ₹3,100 crores | +5% QoQ; base US generics gained share on volume expansion and new launches; 11 product launches, 9 ANDA approvals, 5 ANDA filings in the quarter |
| Consumer Wellness | ₹1,430 crores | +67% YoY; Comfort Plus portfolio included; domestic +5% (skin & hair +35%, food & nutrition +16%, seasonal brands soft); international +25% like-to-like |
| Medical Devices | ₹280 crores | Steady; investing in orthopedics, cardiology, and nephrology (high-end dialyzer membrane facility) |
| US Branded Share of US Revenue | ~10% | Rare disease (Sentient) ~$60M + 505(b)(2) cluster; expected to cross 15% by year-end with Assertio consolidation |
| Other Expenses (excl R&D) Run-Rate | ₹1,900-2,000 cr/quarter | ~80% of YoY increase driven by acquisitions (Zylidac, Assertio) and freight; elevated run-rate to continue in FY27 |
Geographic & Segment Commentary
India Formulations: Delivered 20% YoY growth with broad-based outperformance. Chronic portfolio growing >20%, innovation assets (Saro, Desi) up 30-45%, and biologics scaled significantly post-genericization. Semaglutide remains a small but fast-scaling contributor—Zydus is now the largest innovator-generic semaglutide player in India. Management confident of sustaining mid-teens growth (300-500 bps above market) for the year.
International Market Formulations: Grew 34% YoY to ₹970 crores. Established markets (France, Spain) recovered to strong growth; UK scaled faster than expected. New geographies are monetizing first-generic and innovative launches. Europe has transformed from a difficult business into a growth engine over the past year.
North America (US & Canada): US base generics gained share via volume expansion and launches (11 new products, 9 ANDA approvals, 5 filings). Mirabegron remains a semi-exclusive, highly profitable franchise, though royalty/amortization costs temporarily compress reported gross margin. 180-day CGT exclusivity secured on a recent launch. US branded now ~10% of US revenue—Saroglitazar NDA under priority review (target FY28 launch), Assertio acquired to add Rolvedon (run rate ₹15-20M/quarter). Canada: 2 ANDS approvals, 2 product launches. Biosimilar scale-up in US expected around calendar 2029.
Consumer Wellness: Domestic portfolio grew 5% (skin & hair +35%, food & nutrition +16%; seasonal soft due to mild summer). Comfort Plus contributed to a 67% reported YoY gain; like-to-like international wellness grew 25%. Management guides to strong double-digit growth for FY27 from this segment.
Innovation Pipeline: 5 ANDAs filed, 9 US approvals (4 tentative), ~30-40 launches planned for FY27 (including specialty). Saroglitazar granted FDA priority review for PBC (launch readiness for FY28); Decilustat (sickle cell disease, first-in-class) received Indian Phase 3 approval with ICMR; second ADC biosimilar entered Phase 3 in India; viral typhoid conjugate vaccine completed Phase 2; chickenpox vaccine Phase 1 started; MR vaccine dossier accepted by WHO. Two Phase 3 trials ongoing for Usnoflast (ALS, 240 patients [absorbed under ongoing Phase 2b], readout late CY28; ulcerative colitis Phase 2a data good, next Phase 2b/3 under evaluation).
Company-Specific & Strategic Commentary
Branded Portfolio Transition: Branded share of revenue crossed 55% in Q1 FY27, from ~50% in FY26. Management targets branded share exceeding two-thirds of revenue over the medium term, with EBITDA margin improving toward 28-30% over a 5-year horizon as investments in Saro and new capabilities mature.
US Specialty Build-Out: Completed acquisition of Essercio Holdings (Assertio) in Q1; purchase price allocation (12-month window) will be largely allocated to intangibles (brand and commercial platform). Combined with Sentience (rare disease) and 505(b)(2) franchise (19 in-house + 8 partnered assets; ~7 launches, 10+ approvals in Liquids segment so far), US branded should cross 15% of US revenue by FY27-end.
Sri Lanka JV: Entered joint venture with Sunshine Healthcare to establish a pharmaceutical manufacturing facility in Sri Lanka, supporting local production and reducing import dependence.
China Opportunity for Zydus (Zyfill): Partner achieved approval in China; API supplied for local formulation manufacturing. NRDL reimbursement listing remains the key gating step—management expects clarity in 2-3 quarters. Peers commercially generated $200M+ in the Chinese CKD/anemia market; Zydus sees meaningful long-term potential without reflecting it in current guidance.
Manufacturing/Facilities: Zydus facility received EIR with VAI classification post-GMP surveillance inspection (April-May 2026). India injectables facility (Zydus Lifesciences Ltd) under close regulatory watch following inspection outcome. CapEx of ₹1,500-1,600 crores guided for FY27 across SEZ 3, capacity expansions (Muraiya, Bua, Baddi, Unit 2/3), new formulation R&D center, biologics DS facility, and one-time wellness land acquisition.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | "Strong double-digit" | Q1 +22% YoY; India mid-teens (300-500 bps above market), US single-digit, IMF strong double-digit. Q1 beat may not be linear—management stays with guidance despite strong start |
| EBITDA Margin | ≥24% for FY27 | H2 will absorb increased Saro launch-readiness spend; margin held at 24.1% in Q1 despite acquisition costs and Mirabegron royalty drag |
| CapEx | ₹1,500-1,600 crores FY27 | SEZ 3, capacity expansions, new R&D center, biologics DS facility, wellness land (one-time) |
| Other Expenses (excl R&D) | ₹1,900-2,000 crores/quarter run-rate | Inclusive of acquisitions and freight; 80% of YoY increase acquisition-driven |
| Saroglitazar (Saro) Launch | April 2028 (FY28) | FDA priority review granted for PBC; peak sales estimate conservative $200-300M, optimistic $400M+; first 2 years investment phase; additional marginal ALP trial to expand indication size |
| US Branded Share of US Revenue | >15% by FY27-end | Driven by Assertio consolidation (₹15-20M/quarter run-rate) and existing branded portfolio scale-up |
| US Biosimilars | Meaningful scale-up in calendar 2029 | Ranivizumab launched Q1; PFS and additional products in pipeline; India/EM biosimilars already profitable and scaled |
| Long-term Margin Aspiration | 28-30% EBITDA in ~5 years | Assumes branded share reaches two-thirds of revenue and investments in Saro/US specialty mature |
| Other Pipeline Exclusions | Zydus China, Usnoflast (ALS), new indications | Not reflected in near-term guidance; China NRDL decision in 2-3 quarters; ALS readout late CY28/early CY29 |
Risks & Constraints
| Risk | Context |
|---|---|
| Saroglitazar Execution Risk | Launch cost profile and ramp assumptions hinge on PBC market formation. Management notes competitors have upgraded outlooks, supporting larger market size; but first 2 years will be investment-only with peak sales between $200-400M. Failure to secure U.S. reimbursement or below-expected uptake would delay margin accretion toward 28-30% |
| Margin Dilution from Acquisitions & Royalties | Mirabegron royalty arrangement and Assertio/Zylidac purchase accounting are temporarily compressing gross margin and inflating other expenses (₹1,900-2,000 cr/quarter run-rate). Depreciation elevated until Q2 FY28 (Mirabegron settlement amortization). 24% EBITDA margin guidance assumes these costs don't escalate further |
| Regulatory Actions | Zydus Lifesciences facility received EIR with VAI classification following April-May 2026 GMP inspection—a favorable but not clean outcome; continued surveillance could restrict future product supply or impact U.S. approvals. No commentary on remediation timeline or additional inspections |
| Competitive Pressure in Semaglutide/India Chronic | Management states 20% growth is largely driven by innovation, biosimilars, and chronic portfolio, not semaglutide; but semaglutide remains a crowded market with pricing/market share risks. Multiple new entrants could compress margins in the GLP-1 space |
| China/Global Expansion & Reimbursement Delays | Zydus China approval achieved, but NRDL reimbursement listing is pending; uptake and revenue visibility subject to 2-3 quarter regulatory clarity. Dossier for MR vaccine accepted by WHO but timelines unconfirmed |
| FX and Macros | Strong emerging market and EU growth could moderate if currencies weaken or Europe macro deteriorates. Management did not hedge commentary or quantify FX sensitivity |
Q&A Highlights
FY27 Guidance and Growth Expectation
- Question: With Q1 showing 22% growth, should we expect upward revision from the "strong double-digit" FY27 guidance? (Kunal Dhamesha, Macquarie)
- Answer: Management stays with existing guidance of strong double-digit growth. India to grow mid-teens (300-500 bps better than market), US single-digit, IMF strong. Innovation and biosimilar momentum in India exceeded internal expectations. (Sharvil Patel)
Cost Structure, Margins, and Operating Expenses
- Question: Other expenses rose sharply YoY and QoQ. How should we model opex with Assertio and Saro spend? Is the 24% margin guidance intact? (Neha Manpuria, Bank of America)
- Answer: Guidance maintained at 24%+. Other expenses run-rate excluding R&D is ₹1,900-2,000 crores/quarter, all inclusive. ~80% of the YoY increase is acquisition-driven (Zylidac, Assertio, freight). Saro costs increase in H2 but are already baked into margin guidance. (Tushar Shroff, Sharvil Patel)
CapEx and Investment Allocation
- Question: What's driving the sharp CapEx increase, and what is FY27 guidance? (Neha Manpuria)
- Answer: ₹1,500-1,600 crores for FY27, largely from SEZ 3 construction, capacity expansions (Muraiya, Bua, Baddi, Unit 2/3), a new larger formulation R&D center, the new Carty biologics/vaccine DS facility, and a one-time land acquisition for wellness. Not one single item except the wellness land. (Sharvil Patel)
Saro (Saroglitazar) Launch and Market Opportunity
- Question: With PBC approval near, how should we think about market share, launch costs, and peak sales? Any read on indication expansion? (Neha Manpuria, Kunal Dhamesha, Surya Patra)
- Answer: Launch targeted April 2028 (FY28). Conservative peak sales $200-300M, optimistic $400M+. Competitors have upgraded market outlooks, supporting a bigger patient pool. First 2 years are investment phase. An additional marginal ALP study will expand addressable market; expanded indication readout is 2-3 years out. Launch spend increases in H2 FY27. (Sharvil Patel)
US Branded Portfolio Breakup
- Question: How is the ~10% US branded revenue composed, and where does Assertio fit? (Saion Mukherjee, Nomura)
- Answer: Rare disease/Sentience ~$60M; remaining $60-70M from the 505(b)(2) cluster. Assertio adds from next quarter at ₹15-20M/quarter run-rate, pushing branded to >15% of US revenue by year-end. 505(b)(2) portfolio: 19 in-house + 8 licensed products; ~4+ commercialized, going-out business rate below expectations but improving next fiscal year. (Sharvil Patel)
India Growth Drivers and Biologics
- Question: Beyond the 20% growth, what are the sustainable drivers over 2-3 years? (Saion Mukherjee)
- Answer: Chronic therapies growing >20% (July AVACS shows continued traction); Saro/Desi growing 30-45% and scaling; biologics scaled well post-genericization (including biosimilars); semaglutide is a small contributor but is building fastest. Vaccines on track for ₹300-400 crores target. Management sees sustainability across these pillars. (Sharvil Patel)
International Formulations Engine
- Question: What's driving the 34% growth, and is it sustainable? (Saion Mukherjee)
- Answer: Three drivers: (1) core emerging markets growing strongly; (2) EU turnaround—France and Spain delivering, UK scaling faster than expected; (3) new market entries leveraging innovative/first-generic launches. All three are expected to continue. (Sharvil Patel)
Depreciation, Amortization, and Mirabegron
- Question: Depreciation jumped sequentially; is this level sustainable? (Bino Pathiparampil, Elara)
- Answer: Largely acquisition-related plus licensing amortization from the Mirabegron settlement, which runs through Q1 FY28. Specific numbers not disclosed due to confidentiality. Mirabegron, despite royalties, is a highly profitable semi-exclusive franchise and a net positive. (Tushar Shroff, Sharvil Patel)
Long-Term Margin Trajectory
- Question: With branded mix moving to two-thirds, where do EBITDA margins settle from an FY30 perspective? (Saion Mukherjee)
- Answer: Explicit target of 28-30% EBITDA margins over a 5-year horizon. First couple of years remain investment-heavy (Saro, R&D), but branded scale-up should drive steady margin expansion. (Sharvil Patel)
China Zydus Opportunity
- Question: What is the launch status and revenue potential for Zydus (partnered) in China? (Unidentified analyst)
- Answer: Approved in China; API supplied and formulation manufacturing enabled. NRDL reimbursement listing is the gating step—expect clarity in 2-3 quarters. Peers generate $200M+ in the Chinese CKD anemia market; Zydus views it as a meaningful long-term contributor without including it in current guidance. (Sharvil Patel)
Key Takeaway
Zydus opened FY27 with 22% YoY revenue growth to ₹8,020 crores, 24.1% EBITDA margin, and net profit of ₹940 crores—exceeding market expectations on the top line while holding margin guidance at 24%+. Growth was broad-based: India branded +20%, IMF +34%, consumer wellness +67% (including Comfort Plus), and US branded reaching 10% of US revenue. Strategic momentum centered on the branded mix (now >55% of revenue) with three key catalysts: Saroglitazar (priority review, FY28 US launch with $200-400M peak sales projection), Assertio acquisition (₹15-20M/quarter run-rate), and a 505(b)(2) pipeline (19 in-house + 8 partners, 11 US product launches in the quarter). Management guided FY27 CapEx at ₹1,500-1,600 crores, EBITDA margins of 24%+ (with H2 absorbing higher Saro spend), and reiterated a long-term aspiration of 28-30% margins as branded share reaches two-thirds over 5 years. Key watch items: incremental expenses trending at ₹1,900-2,000 crores/quarter, Mirabegron amortization through Q1 FY28, regulatory follow-through post-VAI at Zydus Lifesciences facility, and India's sustained outperformance (mid-teens) against a high base.